产品
编 号：F340941
分子式：C17H21ClN4O3S2
分子量：428.96
分子式：C17H21ClN4O3S2
分子量：428.96
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 376640-41-4
产品详情
生物活性：
BVT 2733 is a potent, selective, and orally active non-steroidal 11β-hydroxydehydrogenase 1 (11β-HSD1) inhibitor. BVT 2733 is potently against the mouse enzyme (IC50=96 nM) over the human enzyme (IC50=3341 nM). BVT 2733 has the potential for the study of arthritis and obesity related disease.
体内研究：
BVT-2733 (oral administration; 100 mg/kg; twice daily; 2 weeks) attenuates the arthritis severity and anti-CII level and decreases the levels of serum TNF-α, IL-1β, IL-6 and IL-17 in CIA mice.BVT 2733 (oral administration; 100 mg/kg; dosed (09.00 and 17.00 h); last 4 weeks) exhibits decreased body weight and enhanced glucose tolerance and insulin sensitivity when it compares to control mice. It also down-regulated the expression of inflammation-related genes including monocyte chemoattractant protein 1 (MCP-1), tumor necrosis factor alpha (TNF-α) and the number of infiltrated macrophages within the adipose tissue in vivo.Animal Model:Collagen-induced arthritis (CIA)?mice
Dosage:100 mg/kg
Administration:Oral administration; twice daily; 2 weeks
Result:Reduced synovial inflammation and joint destruction.
Animal Model:C57BL/6J mice
Dosage:100 mg/kg
Administration:Oral administration; dosed (09.00 and 17.00 h); last 4 weeks
Result:Improved metabolic homeostasis and suppressed the inflammation of adipose tissue in diet-induced obese mice.?
体外研究：
BVT 2733 (100 μM; 24 hours) co-treatment with PA (100 μM) reduces MCP-1 expression in fully differentiation adipocytes.BVT 2733 (50-100 μM; 24 hours) reduces the inflammation protein levels (MCP-1, IL-6) in medium?in J774.1 macrophages by Elisa.
BVT 2733 is a potent, selective, and orally active non-steroidal 11β-hydroxydehydrogenase 1 (11β-HSD1) inhibitor. BVT 2733 is potently against the mouse enzyme (IC50=96 nM) over the human enzyme (IC50=3341 nM). BVT 2733 has the potential for the study of arthritis and obesity related disease.
体内研究：
BVT-2733 (oral administration; 100 mg/kg; twice daily; 2 weeks) attenuates the arthritis severity and anti-CII level and decreases the levels of serum TNF-α, IL-1β, IL-6 and IL-17 in CIA mice.BVT 2733 (oral administration; 100 mg/kg; dosed (09.00 and 17.00 h); last 4 weeks) exhibits decreased body weight and enhanced glucose tolerance and insulin sensitivity when it compares to control mice. It also down-regulated the expression of inflammation-related genes including monocyte chemoattractant protein 1 (MCP-1), tumor necrosis factor alpha (TNF-α) and the number of infiltrated macrophages within the adipose tissue in vivo.Animal Model:Collagen-induced arthritis (CIA)?mice
Dosage:100 mg/kg
Administration:Oral administration; twice daily; 2 weeks
Result:Reduced synovial inflammation and joint destruction.
Animal Model:C57BL/6J mice
Dosage:100 mg/kg
Administration:Oral administration; dosed (09.00 and 17.00 h); last 4 weeks
Result:Improved metabolic homeostasis and suppressed the inflammation of adipose tissue in diet-induced obese mice.?
体外研究：
BVT 2733 (100 μM; 24 hours) co-treatment with PA (100 μM) reduces MCP-1 expression in fully differentiation adipocytes.BVT 2733 (50-100 μM; 24 hours) reduces the inflammation protein levels (MCP-1, IL-6) in medium?in J774.1 macrophages by Elisa.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备